<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487773</url>
  </required_header>
  <id_info>
    <org_study_id>RNN-87-06-KE</org_study_id>
    <nct_id>NCT00487773</nct_id>
  </id_info>
  <brief_title>Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma</brief_title>
  <official_title>Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma - Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to check if inhaled glucocorticosteroids (iGCS) have influence on
      bone condition (if iGCS increases risk of osteoporosis and bone fraction) in children with
      asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is the most prevalent chronic disease of respiratory tract, the largest frequency is
      noticed in children. iGCS are the basic group of drugs in asthma, because of inflammatory
      character of disease. All iGCS are absorbed to the systemic circulation (small amounts)
      despite of local exposition in lungs and possess systemic effects. The purpose of trial is to
      check if iGCS have influence on bone condition (if iGCS increases risk of osteoporosis and
      bone fraction) in children with asthma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Markers of bone metabolism (from serum and urine)</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms score (based on PAQLQ), spirometry</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>budesonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D3 vitamin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>montelukast sodium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>salbutamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>budesonide</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D3 vitamin</intervention_name>
    <description>D3 vitamin</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast sodium</intervention_name>
    <description>montelukast sodium</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salbutamol</intervention_name>
    <description>salbutamol</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allergic only to house dust mites

          -  Never treated chronically (longer than at least 3 months) with anti-asthmatic drugs

          -  Newly-diagnosed or non-treated asthma

          -  Must be able to inhale drugs

        Exclusion Criteria:

          -  Other allergic diseases requiring treatment with glucocorticosteroids

          -  Other chronic diseases

          -  Asthma exacerbation

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malgorzata Olszowiec-Chlebna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iwona Stelmach, MD, PhD, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics and Allergy, Medical University of Lodz</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2007</study_first_submitted>
  <study_first_submitted_qc>June 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2007</study_first_posted>
  <last_update_submitted>April 12, 2010</last_update_submitted>
  <last_update_submitted_qc>April 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Iwona Stelmach MD, PhD, Prof</name_title>
    <organization>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</organization>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>children</keyword>
  <keyword>inhaled glucocorticosteroids</keyword>
  <keyword>bone metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

